NCT06690970

Prostate Specific Membrane Antigen PET/CT Imaging in PSMA-Related Disease Patients

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 500 (estimated)
• Sponsor: Tianjin Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Accepted

Summary

To evaluate the potential usefulness of 68Ga/18F-PSMA/PSFA positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various PSMA-related disease patients.

Detailed description

Subjects with various PSMA-related disease patients underwent 68Ga/18F-PSMA/PSFA PET/CT either for an initial assessment or for recurrence detection. Lesions uptake was quantified by the maximum standard uptake value (SUVmax). The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of 68Ga/18F-PSMA/PSFA PET/CT were calculated.

Conditions

• PSMA-related Disease
• Prostate Cancer
• Positron Emission Tomography
• Metastasis
• FAP

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	68Ga/18F-PSMA/PSFA	Each subject receive a single intravenous injection of 68Ga/18F-PSMA/PSFA, and undergo PET/CT imaging within the specificed time.

Timeline

• Start date: 2020-09-01
• Primary completion: 2027-12-01
• Completion: 2027-12-01
• First posted: 2024-11-15
• Last updated: 2025-08-11

Locations

2 sites across 1 country: China